Although multiple myeloma remains incurable, treatment advances during the past several years have dramatically improved clinicians’ ability to slow progression of the disease.
Most recently, novel T-cell-directed immunotherapies, such as chimeric antigen receptor T cells and bispecific antibodies, have extended survival and improved quality of life for many patients.
For those with advanced multiple myeloma, the impact of these treatments has been profound, according to Samer Al Hadidi, MD, MS, FACP, assistant professor of medicine at University of Arkansas for Medical Sciences and
